1. The use of a TRPA1 antagonist of formula (XII) or (D): or a pharmaceutically acceptable salt thereof, wherein 'Het' is selected from the group consisting of: R, R and R, which may be the same or different, independently hydrogen (C1-C4) alkyl； R, R, R, R, R and R, which may be the same or different, are in each case independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, amino, substituted or unsubstituted alkyl , alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkylalkoc si, aryl, arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring and heterocyclylalkyl in the manufacture of a composition for inhalation in effective amounts of said TRPA1 antagonist for treating asthma or COPD in an object. 2. The use of a TRPA1 antagonist of formula (XII) or (D): or a pharmaceutically acceptable salt thereof, wherein 'Het' is selected from the group consisting of: R, R and R, which may be the same or different, independently represent hydrogen (C1 -C4) alkyl； R, R, R, R, R and R, which may be the same or different, are in each case independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, amino, substituted or unsubstituted alkyl, alkoxy , haloalkyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkylalkoc and, aryl, arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring, heterocyclylalkyl, when manufacturing compositions for inhaled administration in effective amounts of said antagonist TRPA1 to reduce the number of eosinophils or neutrophils and / or increasing FEV1 n1. Применение антагониста TRPA1 формул (XII) или (D):или их фармацевтически приемлемой соли,при этом 'Het' выбран из группы, включающей:R, Rи R, которые могут являться одинаковыми или различаться, независимо друг от друга представляют собой водород (С1-С4) алкил；R, R, R, R, Rи R, которые могут являться одинаковыми или различаться, в каждом случае независимо выбраны из гр
